Cancer Biomarkers: Are We Ready for the Prime Time?

Mishra, Alok; Verma, Mukesh

doi:10.3390/cancers2010190

Cited by 201 publications

(155 citation statements)

References 107 publications

(120 reference statements)

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…1 Cancer biomarkers are the chemical substances that are related to malignant tumors and can be found in blood, urine, stool, other bodily fluids, or tissues of affected patients. 2,3 Growth factor receptors, peptide growth factors, signal transduction factors, tyrosine kinase and transcription-regulatory proteins are over-expressed in cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Anti-epidermal growth factor receptor conjugated mesoporous zinc oxide nanofibers for breast cancer diagnostics

et al. 2015

View full text Add to dashboard Cite

We report the fabrication of an efficient, label-free, selective and highly reproducible immunosensor with unprecedented sensitivity (femto-molar) to detect a breast cancer biomarker for early diagnostics. Mesoporous zinc oxide nanofibers (ZnOnFs) are synthesized by electrospinning technique with a fiber diameter in the range of 50-150 nm. Fragments of ZnOnFs are electrophoretically deposited on an indium tin oxide glass substrate and conjugated via covalent or electrostatic interactions with a biomarker (antiErbB2; epidermal growth factor receptor 2). Oxygen plasma treatment of the carbon doped ZnOnFs generates functional groups (-COOH, -OH, etc.) that are effective for the conjugation of anti-ErbB2. ZnOnFs without plasma treatment that conjugate via electrostatic interactions were also tested for comparison. Label-free detection of the breast cancer biomarker by this point-of-care device is achieved by an electrochemical impedance technique that has high sensitivity (7.76 kΩ µM ). This sensor is about an order of magnitude more sensitive than the best demonstrated in the literature based on different nanomaterials and about three orders of magnitude better than the ELISA standard for breast cancer biomarker detection. This proposed point-of-care cancer diagnostic offers several advantages, such as higher stability, rapid monitoring, simplicity, cost-effectiveness, etc., and should prove to be useful for the detection of other bio-and cancer markers.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-epidermal growth factor receptor conjugated mesoporous zinc oxide nanofibers for breast cancer diagnostics

et al. 2015

View full text Add to dashboard Cite

show abstract

“…CD44 is the most familiar CSC marker that has previously been identified in various solid malignancies such as breast, CNS, colon, prostate and pancreas (Mishra and Verma, 2010). In both HNSCC cell lines and primary tissues, CD44+ subpopulation demonstrated its tumourigenic potential, tumour sphere formation and chemo-resistance.…”

Section: Cd44mentioning

confidence: 98%

Cancer Stem Cells and Stemness Markers in Oral Squamous Cell Carcinomas

Patel¹,

Shah²,

Shah³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…By using this technology, scientists could isolate and study many potential biomarker proteins (Chandra et al, 2011). Protein microarrays can be miniaturized to contain tens of thousands of capture features arranged in a grid, each specific for a certain type of a protein (Mishra and Verma, 2010). Thus, they are considered a multiplexed device, and can test for multiple biomarkers simultaneously, which is essential for clinical use (Rusling et al, 2010).…”

Section: Necessary Equipment and Technologies For Cancer Proteomics Amentioning

confidence: 99%

Implementation of Proteomics for Cancer Research: Past, Present, and Future

Karimi

Shahrokni²,

Ranjbar³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cancer is the leading cause of the death, accounts for about 13% of all annual deaths worldwide. Many different fields of science are collaborating together studying cancer to improve our knowledge of this lethal disease, and find better solutions for diagnosis and treatment. Proteomics is one of the most recent and rapidly growing areas in molecular biology that helps understanding cancer from an omics data analysis point of view. The human proteome project was officially initiated in 2008. Proteomics enables the scientists to interrogate a variety of biospecimens for their protein contents and measure the concentrations of these proteins. Current necessary equipment and technologies for cancer proteomics are mass spectrometry, protein microarrays, nanotechnology and bioinformatics. In this paper, we provide a brief review on proteomics and its application in cancer research. After a brief introduction including its definition, we summarize the history of major previous work conducted by researchers, followed by an overview on the role of proteomics in cancer studies. We also provide a list of different utilities in cancer proteomics and investigate their advantages and shortcomings from theoretical and practical angles. Finally, we explore some of the main challenges and conclude the paper with future directions in this field.

show abstract

Cancer Biomarkers: Are We Ready for the Prime Time?

Cited by 201 publications

References 107 publications

Anti-epidermal growth factor receptor conjugated mesoporous zinc oxide nanofibers for breast cancer diagnostics

Anti-epidermal growth factor receptor conjugated mesoporous zinc oxide nanofibers for breast cancer diagnostics

Cancer Stem Cells and Stemness Markers in Oral Squamous Cell Carcinomas

Implementation of Proteomics for Cancer Research: Past, Present, and Future

Contact Info

Product

Resources

About